Regeneron Pharmaceuticals' Operating Income fell 1113.92% to $879.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year decrease of 1034.4%. This contributed to the annual value of $3.6 billion for FY2025, which is 1034.4% down from last year.
Regeneron Pharmaceuticals' Operating Income amounted to $879.9 million in Q4 2025, which was down 1113.92% from $1.0 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Operating Income ranged from a high of $3.3 billion in Q2 2021 and a low of $591.7 million during Q1 2025
For the 5-year period, Regeneron Pharmaceuticals' Operating Income averaged around $1.3 billion, with its median value being $1.1 billion (2022).
Its Operating Income has fluctuated over the past 5 years, first skyrocketed by 40993.3% in 2021, then plummeted by 6684.09% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Operating Income stood at $2.6 billion in 2021, then plummeted by 56.56% to $1.1 billion in 2022, then fell by 15.16% to $972.9 million in 2023, then rose by 1.78% to $990.2 million in 2024, then decreased by 11.14% to $879.9 million in 2025.
Its last three reported values are $879.9 million in Q4 2025, $1.0 billion for Q3 2025, and $1.1 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value